Lineage Cell Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2173 Salk Ave Ste 200, Carlsbad, Califor...Phone Number
(442) 287-8990Website
www.lineagecell.comRevenue
$14.8 MillionStock Symbol
LCTXIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
2
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration; (ii) OPC1, an oligRead more
Lineage Cell Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
RH
Manager, Financial Planning & Analysis
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lineage Cell Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Lineage Cell Therapeutics launches new products
Lineage Cell Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Lineage Cell Therapeutics
Check if Lineage Cell Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Lineage Cell Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Lineage Cell Therapeutics has new funding data
Check out if Lineage Cell Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Lineage Cell Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Lineage Cell Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Lineage Cell Therapeutics
Compare insights from companies similar to Lineage Cell Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lineage Cell Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Lineage Cell Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Lineage Cell Therapeutics.
Lineage Cell Therapeutics financials insights
Gather financial insights about Lineage Cell Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Corporate Investment
$24.6M
2021
Other Financing Round
$35.9M
Lineage Cell Therapeutics Tech Stack
A closer look at the technologies used by Lineage Cell Therapeutics
See more technologies
Most Recent Scoops
Project
Lineage Cell Therapeutics has developed a proprietary cryopreservation protocol for its Core One CENC product candidate, achieving clinically and commercially attractive viability and recovery levels across all manufacturing steps, with a ready-to-use thaw-and-inject format intended to provide a competitive advantage.
Bioengineering
Project
utilizes a two-tiered banking system for both its Oprigen and Core One programs, with a master cell bank and working cell bank structure capable of generating an estimated 30 million doses of a product candidate from a single production run.
Manufacturing Operations
Project
Lineage Cell Therapeutics has determined that its 5D expansion process supports high-quality CENC production at significantly greater scale than a 2D modality, projecting the ability to generate millions of doses of the Core One product candidate from its current banking system at a cost of goods expected to be below four figures per dose.
Research & Development, Pharmaceuticals
Project
Lineage Cell Therapeutics has established a transepithelial resistance test as a potency assay for its Core One program to ensure batch-to-batch consistency, meeting an FDA requirement for clinical use, while continuing to optimize conditions for the final expansion steps.
Quality Assurance, Research & Development, Clinical Operations
Project
Medical Research, Clinical Operations
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lineage Cell Therapeutics
Sign Up For FreeTo access detailed company insights
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminal... Read More
